U.S. Markets open in 6 hrs 36 mins
  • S&P Futures

    3,601.00
    +25.00 (+0.70%)
     
  • Dow Futures

    29,791.00
    +245.00 (+0.83%)
     
  • Nasdaq Futures

    11,968.75
    +63.50 (+0.53%)
     
  • Russell 2000 Futures

    1,837.40
    +20.30 (+1.12%)
     
  • Crude Oil

    43.52
    +0.46 (+1.07%)
     
  • Gold

    1,826.20
    -11.60 (-0.63%)
     
  • Silver

    23.45
    -0.18 (-0.77%)
     
  • EUR/USD

    1.1854
    +0.0008 (+0.0711%)
     
  • 10-Yr Bond

    0.8570
    0.0000 (0.00%)
     
  • Vix

    22.66
    -1.04 (-4.39%)
     
  • GBP/USD

    1.3337
    +0.0015 (+0.1094%)
     
  • USD/JPY

    104.4720
    -0.0160 (-0.0153%)
     
  • BTC-USD

    18,357.72
    -13.62 (-0.07%)
     
  • CMC Crypto 200

    367.65
    +6.22 (+1.72%)
     
  • FTSE 100

    6,333.84
    -17.61 (-0.28%)
     
  • Nikkei 225

    26,165.59
    +638.22 (+2.50%)
     

Seres Therapeutics to Present at the Jefferies Next Generation IBD Therapeutics Summit

·1 min read

Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will present a corporate overview at the Jefferies Next Generation IBD Therapeutics Summit on Wednesday, September 23 at 8:00 a.m. E.T.

A webcast of the presentation will be available under the "Investors and Media" section of Seres’ website and will be archived for 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc., (Nasdaq: MCRB) is a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres’ SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres’ SER-287 program has obtained Fast Track and Orphan Drug designations from the FDA and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres is developing SER-401 in a Phase 1b study in patients with metastatic melanoma, SER-301 for ulcerative colitis and SER-155 to prevent mortality due to gastrointestinal infections, bacteremia and graft versus host disease. For more information, please visit www.serestherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200922005219/en/

Contacts

PR Contact
Lisa Raffensperger
lisa@tenbridgecommunications.com

IR Contact
Carlo Tanzi, Ph.D.
ctanzi@serestherapeutics.com